North America Pharma Cloud Services Market

Market Outlook

The North America pharma cloud services market, valued at USD 5.7 billion in 2025, is projected to reach USD 6.8 billion in 2026 and USD 21.2 billion by 2035, representing a CAGR of 13.5% during the forecast period from 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

Market Size & Trends

• In terms of area of application, drug discovery holds the highest share of the market.
• With respect to type of cloud service, software as a service dominates the current market.
• Based on the type of cloud, hybrid cloud (nearly 45%) captures the largest share of the market; this trend is unlikely to change in the future.
• In terms of end user, pharmaceutical and life sciences companies hold the highest share of the current market.

Key Market Statistics

• Market Size in 2026: $6.8 Billion
• Estimated Market Size in 2035: $21.2 Billion
• CAGR (2026-2035): 13.5%

Market Introduction

The pharmaceutical industry is undergoing a steady digital transformation, driven by the need to manage growing volumes of complex data across research, development, clinical operations, manufacturing, and commercialization. In this evolving landscape, cloud computing has emerged as a critical infrastructure layer, enabling secure data storage, seamless collaboration, advanced analytics, and faster information exchange across geographically dispersed teams.

While healthcare and pharmaceutical organizations were initially cautious in adopting cloud technologies due to concerns around data privacy, security, and regulatory compliance, the availability of compliant cloud environments has significantly improved confidence in their use. This is particularly evident in North America, where a mature healthcare IT ecosystem, strong regulatory frameworks, and the presence of leading pharmaceutical and biotechnology companies have created a favorable environment for cloud adoption.

As pharmaceutical companies generate large volumes of genomic, clinical, imaging, real-world, and manufacturing data, traditional IT systems are becoming increasingly inadequate to support modern R&D requirements. Cloud-based platforms address this gap by offering scalable computing power, flexible storage, and advanced data processing capabilities.

Further, in drug discovery, these platforms allow researchers to analyze large and diverse datasets more efficiently, supporting faster target identification, lead optimization, and candidate selection. As pharmaceutical companies integrate artificial intelligence and machine learning into early-stage research, cloud computing is becoming a key enabler of data-driven drug discovery.

The role of cloud computing becomes even more significant as drug candidates move from discovery into development. Clinical development involves multiple stakeholders, large patient datasets, complex trial designs, and stringent documentation requirements. Cloud-based solutions help streamline these processes by supporting clinical trial management, decentralized trial models, predictive analytics, pharmacovigilance, regulatory submissions, and real-time collaboration between sponsors, contract research organizations, investigators, and regulators.

In North America, where clinical trial activity is high and regulatory expectations are well-defined, pharmaceutical companies are increasingly adopting cloud platforms to improve trial efficiency, strengthen compliance readiness, and accelerate decision-making across development programs. Beyond R&D and clinical development, cloud technologies are also becoming increasingly important in pharmaceutical manufacturing and supply chain management.

The industry continues to face pressure to improve transparency, ensure product quality, support precision medicine, reduce inefficiencies, and strengthen resilience across complex global supply networks. Cloud-based systems enable better visibility into manufacturing operations, quality control processes, inventory movement, serialization, and supplier coordination. For North American pharmaceutical companies, these capabilities are particularly valuable as they seek to modernize legacy infrastructure, enhance compliance with stringent quality standards, and build more agile manufacturing ecosystems.

The growing relevance of cloud computing is also reflected in the strategies of leading pharmaceutical companies. Organizations such as Pfizer, Novartis, and AstraZeneca have increasingly leveraged platforms such as AWS and Microsoft Azure to support data management, AI-enabled research, clinical workflows, and enterprise-wide digital transformation. These initiatives demonstrate that cloud adoption is no longer limited to basic IT modernization; it is becoming a strategic priority for improving innovation capacity, operational efficiency, and time-to-market.

As AI integration, cybersecurity frameworks, multi-cloud deployment, and regulatory-grade data platforms continue to advance, the pharma cloud services market in North America is expected to witness sustained growth during the forecast period.

Pharma Cloud Services Ecosystem by Application Area

Market Segmentation

Based on the research, we have segmented the North America Pharma Cloud Services Market into area of application, type of cloud service, type of cloud and end user.

By Area of Application

• Drug Discovery
• Drug Development
• Drug Manufacturing

By Type of Cloud Service

• Software as a Service
• Infrastructure as a Service
• Platform as a Service
• Others

By Type of Cloud

• Hybrid
• Public
• Private

By End User

• Pharmaceutical and Life Sciences Companies
• CROs
• Others

North America Pharma Cloud Services Market Key Insights

What are the Latest Trends in the North America Pharma Cloud Services Market?

• Rising Adoption of AI-Enabled Cloud Platforms: Pharmaceutical companies in North America are increasingly adopting AI-enabled cloud platforms to accelerate drug discovery, clinical development, regulatory documentation, manufacturing, and commercial operations. As pharma companies handle large volumes of genomic, clinical, imaging, and real-world data, cloud platforms are becoming essential for scalable computing and faster decision-making. In 2026, Merck announced a multi-year collaboration with Google Cloud, valued at up to USD 1 billion, to deploy an agentic AI platform across R&D, manufacturing, commercial, and corporate functions. This indicates a shift from experimental AI pilots toward broader enterprise-level adoption of cloud-based AI in the pharmaceutical industry.
• Growing Use of Cloud-Based AI in Drug Discovery and Development Workflows: Cloud services are increasingly being used to automate complex drug development workflows, particularly across clinical, regulatory, patient safety, and quality functions. This trend is gaining importance as pharmaceutical companies seek faster access to structured and unstructured data, improved cross-functional collaboration, and stronger decision support across the development lifecycle. Notably, AstraZeneca collaborated with AWS to build development assistant, an AI-powered tool developed using Amazon Bedrock Agents. The solution enables clinical, regulatory, patient safety, and quality teams to access insights from structured and unstructured data more efficiently. AWS states that AstraZeneca developed the solution from concept to production in six months and is scaling it to more than 1,000 users.
• Increase in Partnership Activity: Several stakeholders in this domain have entered into partnerships to enhance their offerings. Most of the partnerships reported were instances of platform utilization agreements. This is primarily driven by the need for pharma companies to leverage scalable, secure, and compliant cloud infrastructures that facilitate collaboration across the entire drug lifecycle. Additionally, the pharmaceutical industry's increasing shift toward hybrid and multi-cloud strategies has encouraged the adoption of cloud platforms certified for GxP and other regulatory standards, thereby boosting confidence in cloud migration.

What are the Key Drivers for Market Growth?

The market growth is fueled by various factors, including the rising adoption of virtual clinical trials, which rely on secure, scalable cloud infrastructure to enable remote patient participation. Further, the integration of AI in pharma cloud software also accelerates drug discovery, optimizes clinical trial management, and improves operational efficiency across development and manufacturing processes. Moreover, increasing regulatory requirements for data management and compliance is further prompting pharma companies to adopt cloud solutions that offer validated, secure environments. The market is also supported by demand for scalable, cost-effective Software as a Service (SaaS) applications that improve clinical data management, pharmacovigilance, manufacturing, and commercial operations.

Recent Developments in North America Pharma Cloud Services Market

• In June 2026, Apexon collaborated with Amazon Web Services to deliver agentic AI, cloud-native modernization, and digital engineering solutions for healthcare and life sciences organizations.
• In April 2026, Amazon Web Services launched Amazon Bio Discovery, an AI-powered cloud application designed to accelerate early-stage antibody drug discovery.
• In January 2026, Veeva Systems partnered with BioMarin Pharmaceutical to broaden BioMarin's use of Veeva's cloud-based development and commercial platforms. The collaboration is intended to speed up rare disease drug development by enhancing clinical data management, regulatory processes, and commercialization through integrated, pharma-focused cloud solutions.

Industry Experts on North America Pharma Cloud Services Market

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following discussions:

• Vice President Growth, Small Company, US
• Regional Manager North and South America, Small Company, Switzerland

In addition, the market report includes transcripts from the following third-party discussions:

• Chief Regulatory Officer, Very Large Company, France
• Group Vice President, Research Services, Health & Life Sciences, Very Large Company, US
• Senior Vice President, Life Sciences, Very Large Company, US
• Vice President of R&D Business Consulting, Very Large Company, US
• Global Director, Healthcare & Life Sciences, Very Large Company, US
• Chief Information and Data Officer, Mid-sized Company, US
• Head of AI Consulting, Mid-sized Company, UK
• Managing Director, Mid-sized Company, India
• Head of GTM, Strategic Partnerships & Alliances, Mid-sized Company, Germany
• Technical Lead, Large Company, US

The North America pharma cloud services market is expected to remain growth-oriented, supported by AI adoption, regulatory-grade cloud platforms, and modernization of R&D, clinical, and manufacturing workflows.

Suketu Shah (MD, Soham ERP), stated that, "Pharma companies are using modern technologies like the Internet of Things (IoT), Cognitive Science, AI/ML, blockchain and RPA in unison, with cloud as the foundation. This is helping pharma companies accelerate production while minimizing mistakes and errors, offering radical improvements in distribution and supply chain management."

Market Share Insights

Which Area of Application Accounts for the Largest North America Pharma Cloud Services Market Share?

• In 2026, the drug discovery segment accounts for the largest share of the North America pharma cloud services market and is likely to grow at the highest CAGR (15.2%) during the forecast period.
• This dominance is driven by cloud platforms' ability to accelerate and reduce R&D costs through scalable computing power and AI-driven analytics. By enabling real-time collaboration, ensuring data integrity, and supporting regulatory compliance, these platforms streamline compound optimization and shorten the time-to-market for new drugs.

Will the Pharmaceutical and Life Sciences Companies' Segment Continue to Hold the Highest Share?

• In 2026, the pharmaceutical and life sciences segment occupies the highest share of the North America pharma cloud services market and is likely to grow at a higher CAGR (15.6%) during the forecast period.
• This is driven by the fact that pharma and life sciences organizations have rapidly migrated from legacy systems to cloud platforms to boost innovation, data integration, and speed of operations.

Among Hybrid Cloud, Public Cloud and Private Cloud, Which Segment Holds the Highest Share in the North America Pharma Cloud Services Market?

• In 2026, the hybrid cloud segment is likely to capture the majority of the North America pharma cloud services market size (45%). This is driven by the fact that hybrid cloud has the ability to combine private clouds' security and control with public clouds' scalability and cost efficiency.
• It is worth highlighting that the market share for public cloud is likely to grow at a relatively higher CAGR (15.7%) during the forecast period.

Scope of North America Pharma Cloud Services Market Report